You are viewing the site in preview mode

Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Spectrum of disease in HIV-positive patients presenting to a tertiary care hospital: a retrospective, cross-sectional review in Kumasi, Ghana

  • 1, 2Email authorView ORCID ID profile,
  • 3,
  • 4,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 5
BMC Infectious Diseases201818:419

https://doi.org/10.1186/s12879-018-3332-1

  • Received: 28 March 2018
  • Accepted: 15 August 2018
  • Published:
Open Peer Review reports

Abstract

Background

HIV remains a significant public health dilemma in West and Central Africa. HIV-related morbidity and mortality are unjustly high, yet little is known about the spectrum of complicating comorbidities in HIV-positive patients who are admitted to hospitals in these regions.

Methods

This study involved a retrospective chart review to determine the common comorbidities and mortality rate of HIV-infected patients admitted over a six month period to the internal medicine service at the Komfo Anokye Teaching Hospital (KATH), a tertiary care center in Ghana. Patients admitted with a known or new HIV diagnosis from January to July 2016 were included. Data were collected regarding the number of new versus known cases admitted, the most common presenting complaints, final admitting diagnoses, and causes of mortality in these patients.

Results

During the six-month study period, 250 HIV-positive patients were admitted to KATH, and 245 of these individuals had valid survival time recorded. Of these patients, 145/245 (59.2%) were female. Median age of patients included in the study was 42 years old (IQR 35–51). The mortality rate for HIV patients admitted to the hospital was 35.5% (87 patients). One hundred and forty-five (59.4%) patients had a known history of HIV documented in their patient charts, while the remaining patients were newly diagnosed with HIV during their inpatient stay. Pulmonary tuberculosis predominated among diagnostic findings, with 40.4% of HIV-infected patients diagnosed with the condition while admitted. Patients presenting with neurological symptoms on admission were 2.14 (95% CI: 1.27–3.61) times more likely to die than those without neurological symptoms (p = .004).

Conclusions

Over 40% of HIV-positive patients admitted to KATH were newly diagnosed with HIV at admission. While pulmonary tuberculosis was the most common co-morbidity, patients presenting with neurological symptoms were at higher risk of death. This study suggests that enhanced outpatient screening is needed for early diagnosis and prompt HAART initiation, as well as increased access to diagnostic modalities and treatment for HIV-positive patients with neurological symptoms.

Keywords

  • HIV
  • AIDS
  • Global Health
  • Ghana
  • Epidemiology

Background

Although new HIV infections have declined significantly in western and central Africa in the last decade, these regions still account for 22% of total global infections [1]. The prognosis for persons living with HIV has improved dramatically since the advent of highly active antiretroviral therapy (HAART) [2], but these improvements have lagged behind in resource-poor countries [3]. Of the staggering 6.1 million people living with HIV in West and Central Africa, only 35% were accessing antiretroviral therapy in 2016 [1]. As a result, HIV-related morbidity and mortality remain unjustly high in this region [37]. Patients continue to present to inpatient care with WHO Class III and IV illness and undiagnosed or untreated HIV infection as a result of insufficient case finding, poor linkage to care and treatment failure or default [3, 4, 812]. This undoubtedly contributed to the 310,000 AIDS-related deaths that were reported in 2016 in western and central Africa [1]. In the nation of Ghana in the geographic region of West Africa, 230,000 adults were living with HIV in 2015 [13], but in this population there are currently limited morbidity and mortality studies of HIV-positive adults presenting to hospital.

Several studies in other nations have attempted to evaluate causes of hospitalization in HIV-infected patients and their associated mortality in resource-poor countries in order to better characterize these disparities [7, 11, 1417]. The results are not surprising: most patients present with late stage HIV (WHO Classes III and IV), many have associated tuberculosis morbidity and resultant in-hospital mortality is high [3, 7, 1416]. Regional differences in HIV co-morbidities have been noted within the African continent. For example, in East Africa, Cryptococcus neoformans infection continues to be a major burden of disease in immunocompromised patients [10]; however, the prevalence of cryptococcal antigenemia may be quite low in West Africa [18]. Thus, these studies are needed globally to identify the common HIV-related comorbidities on a regional basis. Epidemiological knowledge about disease presentations can inform better allocation of resources towards the diagnosis and treatment of common clinical presentations.

There are still advances in care that must be pursued in light of global targets in the HIV pandemic. The 90–90-90 goals advocate for substantial increases in case detection, treatment and follow-up care amongst this patient population, with goals of reaching 90% case diagnosis, 90% of patients diagnosed receiving antiretroviral treatment, and 90% of those on treatment achieving undetectable viral loads by the year 2020 [19]. In addition, the INSIGHT [20] and TEMPRANO [21] trials have led to the WHO’s 2015 recommendations for initiation of ART in all patients regardless of CD4 count [22].

In light of these recommendations and targets, our aim was to investigate the rate of known versus new HIV diagnosis as well as morbidity and mortality outcomes for HIV-positive patients admitted to the internal medicine department at the Komfo Anokye Teaching Hospital (KATH) in order to contribute to the development of strategies to improve care of individuals with HIV infection in Ghana.

Methods

Study design and population

This study took place at the Komfo-Anokye Teaching Hospital (KATH), a 1200-bed tertiary hospital located in Kumasi, the capital city of the Ashanti Region of Ghana. Patients are referred to KATH from each of the ten regions of Ghana. Adult patients greater than 18 years old admitted to the internal medicine service at KATH with documented HIV infection were included in the study. The study included patients who were admitted to the hospital with a previous diagnosis of HIV, as well as those who were newly diagnosed during their current admission. Patients without valid dates of admission, discharge or death recorded in the patient chart were excluded from analysis.

Procedures and measurements

This retrospective, cross-sectional, single-center study took place over a six-month period from January to July 2016. The charts of patients who had been discharged or died during this study period of interest were reviewed for HIV status. In order to find relevant cases, physicians and research assistants involved in the study examined the daily discharge and death folders on each internal medicine ward in order to capture all eligible patient records.

For patients found to be HIV-positive, researchers completed a standardized data collection form from the patient chart. The form included demographic information, such as age, sex, and date of admission; presenting symptoms and physical exam findings; information about HIV diagnosis, including known or new diagnosis, HAART history, and HIV clinical staging; laboratory data, when available; and final diagnoses and outcomes (death or discharge). Only prerecorded data available in the patient charts were used for data collection, and no patients or physicians were interviewed for data collection.

Definition of HIV positive status and HAART experience

Patients were considered eligible for review if they were diagnosed with serologically-proven HIV upon current admission to the hospital or if a known prior diagnosis had been documented in the patient chart. A diagnosis was documented as “new” if the patient was diagnosed on current admission to KATH, while a diagnosis was deemed “known” if the patient had ever been previously diagnosed with HIV, even if that diagnosis occurred at a referral hospital just before arriving at KATH. Patients were considered to have HAART experience if the patient’s chart documented that the patient had ever previously been started on HAART or was currently receiving HAART therapy.

Diagnostic methods

Pulmonary tuberculosis was diagnosed when the patient exhibited (1) consistent clinical findings, (2) suggestive chest x-ray, and (3) placement on standard TB treatment. Patients who presented with focal or generalized neurological symptoms suggestive of an intracranial space-occupying lesion unable to obtain head CT were classified as “undifferentiated intracranial space occupying legion (ICSOL)” with a wide differential diagnosis including stroke, toxoplasmosis, brain abscess, tuberculoma or intracranial malignancy. Patients able to undergo head CT were categorized as CT-suggested toxoplasmosis when radiographic evidence revealed multiple, ring-enhancing lesions. Anemia, thrombocytopenia, and pancytopenia were confirmed via laboratory results in the patient chart. A diagnosis of cryptococcal disease was based on a record of serum or CSF cryptococcal antigen result or Indian ink stain result. Other, less common diagnoses listed in patient charts utilized a variety of clinical and laboratory findings to diagnose the patient.

Statistical analysis

All patient records used for the study were assigned a random alpha-numeric identifier in order to protect patient confidentiality. Patient records were entered into a FileMaker 12 Pro (FileMaker, Inc., Santa Clara, California) database. Subsequently, data were extracted from the database and analyzed using SAS version 9.4 (Cary, NC).

Summary frequencies and proportions were used to describe the sample for all nominal characteristics including patients’ sex, transfer from another hospital to KATH, symptoms, and comorbidities. Medians with interquartile range were used to describe all other demographics including patients’ age, months since HIV diagnosis, and laboratory values. Univariable Cox proportional hazards models were used to estimate the risk of mortality following date of admission as a function of patients’ comorbidities and demographic characteristics. In these models, elapsed time was measured in days from date of admission to date of death (if deceased) and living patients were censored on their discharge date. The proportional hazard assumption for each predictor was assessed graphically using Martingale residuals as described by Lin, Wei, and Ying [23].

A multivariable Cox proportional hazards model was used to estimate the adjusted risk of mortality as a function of HAART while controlling for patients’ age, sex, presence of neurological symptoms, clinical stage, ICSOL diagnosis, and pneumonia. These covariates were selected because of their importance on univariable analysis and improvement in multivariable model fit statistics, including Akaike information criterion (AIC).

Ethics clearance

Ethics approval was granted by the Kwame Nkrumah University of Science and Technology and the Komfo Anokye Teaching Hospital ethics review committee (CHRPE/347/15). Consent from individual patients was waived, as this project involved only a retrospective review of patient charts without any acquisition of identifying patient information.

Results

During the six-month study period, 250 HIV-positive patients were admitted to the KATH internal medicine service and 245 of these individuals had valid survival time recorded. Of these patients, 145/245 (59.2%) were female. Median age of patients included in the study was 42 years old (IQR 35–51). Mortality rate during admission was 35.5% (87 patients). One hundred and forty five (59.4%) of the patients admitted had a known history of HIV documented in their patient chart, while the remaining patients were found to have a new diagnosis of HIV during their admission (Table 1).
Table 1

Demographic characteristics and presenting complaints of patients presenting to KATH from January–July 2016

 

Valid N

Total

Female Sex

245

145 (59.2%)

Mdn Age (IQR)

244

42.0 (35.0–50.5)

Mdn Months since HIV diagnosis (IQR)

205

0.82 (0.23–12.29)

Referred to KATH

189

92 (48.7%)

Constitutional Symptoms

240

65 (27.1%)

Neurological Symptoms

239

102 (42.7%)

Pulmonary Symptoms

240

81 (33.8%)

Cardiac symptoms

240

22 (9.2%)

Gastrointestinal Symptoms

241

58 (24.1%)

Other admission reason

243

15 (6.2%)

Known History of HIV

244

145 (59.4%)

HAART

237

99 (41.8%)

Clinical Stage

244

 

 Stage 0

 

1 (0.4%)

 Stage 1

 

20 (8.2%)

 Stage 2

 

3 (1.2%)

 Stage 3

 

112 (45.9%)

 Stage 4

 

108 (44.3%)

Mdn Hemoglobin (IQR)

230

8.65 (6.90–10.90)

Mdn Platelet Count (IQR)

224

269.5 (149.0–377.0)

Unless otherwise noted, valid counts are provided with column proportions. Mdn Median, IQR Interquartile range. HAART Highly active antiretroviral therapy, HIV Human immunodeficiency virus, KATH Komfo-Anokye Teaching Hospital

There was a broad spectrum of patient complaints at the time of admission. Charts were examined for chief presenting complaint and categorized according to the main body system involved in the complaint (Table 1). Pulmonary and neurologic symptoms predominated among presenting patient complaints, with 33.8% and 42.7% of patients experiencing these complaints respectively. A variety of diagnoses were discovered within this patient population (Table 2).
Table 2

Final diagnoses of HIV-positive patients admitted to KATH

 

Valid N

Discharged (N = 158)

Deceased (N = 87)

Total (N = 245)

ICSOL

245

28 (17.7%)

26 (29.9%)

54 (22.0%)

Pulmonary Tuberculosis

245

52 (32.9%)

47 (54.0%)

99 (40.4%)

HIV encephalopathy

244

4 (2.5%)

6 (6.9%)

10 (4.1%)

Bacterial Pneumonia

245

20 (12.7%)

21 (24.1%)

41 (16.7%)

Gastroenteritis

245

17 (10.8%)

8 (9.2%)

25 (10.2%)

Candidiasis

245

33 (20.9%)

15 (17.2%)

48 (19.6%)

Pleural Effusion

245

8 (5.1%)

6 (6.9%)

14 (5.7%)

Hypertension

245

20 (12.7%)

5 (5.7%)

25 (10.2%)

Anemia

245

59 (37.3%)

42 (48.3%)

101 (41.2%)

HIV Associated Nephropathy

245

5 (3.2%)

4 (4.6%)

9 (3.7%)

Hepatitis B

239

7 (4.4%)

6 (6.9%)

13 (5.3%)

Unspecified Diarrhea

245

14 (8.9%)

5 (5.7%)

19 (7.8%)

Valid counts are provided with column proportions. ICSOL Suspected intracranial space occupying lesion, HIV Human immunodeficiency virus, Only diagnoses occurring with N ≥ 10 patients are included in the Table. “Discharged” and “deceased” columns are listed with column proportions

As expected, pulmonary tuberculosis predominated among diagnostic findings, with 40.4% of admitted patients diagnosed with the condition during the course of their stay. Based on neurological findings on exam, 54 (22.0%) of patients were suspected to have an intracranial space occupying lesion (ICSOL). However, only 19 (35.2%) of these patients received a head CT scan. Fourteen of the 19 patients (73.7%) able to undergo head CT scan revealed radiographic evidence of toxoplasmosis (multiple, ring-enhancing lesions). Causes of mortality were varied. Of the 87 patients who died while admitted, 54.0% had pulmonary tuberculosis, while 29.9% had a clinical or radiological diagnosis of ICSOL. Another 29.1% were diagnosed with bacterial pneumonia. Other diagnoses are listed in Table 2.

In this sample of data, there was no meaningful difference in time to death between those receiving and not receiving HAART (p = 0.89) (see Table 3).
Table 3

Univariable analysis of risk of mortality as a function of patient comorbidities and characteristics

 

Valid N

Hazard Ratio

95% Confidence Interval

p

Lower

Upper

Age (per 5 year increase)

244

1.105

0.999

1.222

.052

Male vs Female

245

1.475

0.963

2.258

.07

Referred to KATH: Yes vs No

189

0.828

0.514

1.333

.44

Reason for Admission (Yes vs No)

 Constitutional symptoms

240

0.832

0.512

1.353

.46

 Neurological symptoms

239

2.113

1.362

3.279

.001

 Pulmonary symptoms

240

0.892

0.566

1.407

.62

 Cardiac symptoms

240

0.871

0.433

1.753

.70

 Gastrointestinal symptoms

241

0.538

0.301

0.962

.04

 Other reason for admission

243

1.576

0.783

3.171

.20

Months since HIV diagnosis (per 1 month increase)

205

1.004

0.998

1.009

.18

New vs Known HIV diagnosis

244

0.866

0.554

1.353

.53

HAART: Yes vs No

237

0.969

0.625

1.502

.89

Prophylaxis Medication: Yes vs No

235

1.146

0.675

1.945

.61

HgB (per 1 unit increase)

230

0.996

0.964

1.029

.81

PLT (per 5 unit increase)

224

1.003

0.996

1.010

.43

Febrile Exam: Yes vs No

232

1.342

0.845

2.132

.21

Clinical Stage (vs Stage 0–2)

244

   

.12

 Stage 3

 

2.937

0.707

12.191

.14

 Stage 4

 

3.794

0.918

15.680

.07

Final Diagnoses (Yes vs No)

 ICSOL

245

1.724

1.084

2.742

.02

 ICSOL with CT

56

0.402

0.162

1.000

.0501

 CT-suggestive Toxoplasmosis

245

0.553

0.174

1.756

.32

 Pulmonary TB

245

1.041

0.670

1.619

.86

 Encephalopathy

244

2.133

0.927

4.909

.07

 Pneumonia

245

1.787

1.089

2.931

.02

 Gastroenteritis

245

1.217

0.586

2.527

.60

 Candidiasis

245

0.939

0.536

1.643

.82

 Pleural Effusion

245

0.735

0.317

1.701

.47

 HTN

245

0.610

0.246

1.511

.29

 Anemia

245

1.139

0.744

1.743

.55

 HIV-Associated nephropathy

245

1.331

0.487

3.640

.58

 Hepatitis B

245

1.175

0.511

2.702

.70

 Diarrhea

245

1.001

0.404

2.478

.99

On univariable analysis, neurological symptoms were associated with an increased risk of mortality. Compared to patients without neurological symptoms, those presenting with neurological symptoms as their reason for admission were 2.11 (95% CI: 1.36–3.28) times more likely to die (p = .001). Conversely, patients with gastrointestinal symptoms were less likely to die (HR = 0.54, 95% CI: 0.30–0.96), though it is important to note that the upper end of the confidence interval is approaching a null conclusion (p = .04). Regarding final diagnosis, patients with an ICSOL diagnosis were 1.72 (95% CI: 1.08–2.74) times more likely to die when compared to patients without an ICSOL diagnosis (p = .02), and patients with a diagnosis of pneumonia were 1.79 (95% CI: 1.09–2.93) times more likely to die when compared to patients without a pneumonia diagnosis (p = .02). After controlling for patients’ use of HAART as well as their age, sex, clinical stage, ICSOL diagnosis, and pneumonia, those presenting with neurological symptoms remained at high risk for mortality (HR = 2.14, 95% CI: 1.27–3.61; p = .004) (Table 4).
Table 4

Risk of mortality as a function of multivariable patient comorbidities and characteristics

 

Adjusted Hazard Ratio

95% Confidence Interval

p

Lower

Upper

HAART (Yes vs No)

0.997

0.639

1.555

.99

Age (per 5 year increase)

1.050

0.939

1.173

.39

Male vs Female

1.394

0.890

2.185

.15

Neurological symptoms (Yes vs No)

2.138

1.267

3.608

.004

Clinical Stage (vs Stage 0–2)

   

.27

 Stage 3

3.261

0.777

13.686

.11

 Stage 4

2.895

0.671

12.489

.15

ICSOL (Yes vs No)

0.966

0.503

1.854

.92

Pneumonia (Yes vs No)

1.435

0.817

2.519

.21

Number of events = 81. Overall model significance p = .03

Discussion

The data collected from this study can aid in the development of strategies to reduce the morbidity and mortality of individuals with HIV infection in Ghana. It has identified the need for additional case finding and screening for HIV diagnosis. This study revealed a large number of newly diagnosed cases of HIV, with 40% receiving a new diagnosis during their current admission to the hospital. While some of these patients may have received a previous diagnosis that they chose not to disclose to the physician, there are likely a high number of new cases among patients that had not been recently screened. Thus, there is a need for increased HIV screening at the local level to enroll patients in treatment in order to achieve 90–90-90 targets [19] in the upcoming years.

The results of this study suggest that tuberculosis represents a major comorbidity (40.4%) amongst HIV-positive patients in this region of Ghana. This high prevalence of tuberculosis is similar to another study examining causes of morbidity at other sites in West Africa [4]. Additionally, neurological complaints commonly occurred in this patient population, with 22.0% of presenting patients thought to have an intracranial space occupying lesion on exam. Among these patients, less than half received CT imaging to confirm diagnosis representing a significant diagnostic barrier. This could contribute to the statistically significant association of neurological symptoms with mortality in the region. The possible reasons for not receiving CT imaging are multifactorial and would include high cost to the patient, lack of health insurance coverage for CT imaging, patient refusal, unavailability of CT imaging machines at the facility and mortality prior to receiving imaging during the inpatient hospital stay. Regional differences in causative organisms for meningitis were also highlighted, with five patients presenting with CSF findings consistent with tuberculosis meningitis (data not shown), while no patients had a positive test result recorded on serum or CSF for Cryptococcal infection. This finding exhibited the geographic variability of cryptococcal disease, which is common in eastern Africa [10] but does not appear to be prevalent in Ghana [13].

The results of this study suggest that resource allocation for HIV treatment in this region may be most useful in primary detection of HIV in order to prevent late patient presentation in stage 3 or 4 disease. Tuberculosis diagnosis and treatment must continue to be emphasized, as nearly half of patients diagnosed with pulmonary tuberculosis (47.5%) did not survive until discharge, while over half (54.0%) of all inpatient deaths were related to a tuberculosis diagnosis. Lastly, more resources must be allocated to diagnostic imaging for neurological complaints in HIV patients, as CT scanning is an essential component of diagnosis to differentiate symptoms concerning for intracranial lesions.

There are several potential weaknesses of the study. First, as data collection involved paper chart data retrieval, there are potential missed cases, as charts may have been removed from the ward before data collection was complete. Secondly, misdiagnosis is a possibility, as not all patients were able to undergo necessary investigations to confirm diagnoses, instead undergoing presumptive treatment. This also argues for resource funding from HIV aid groups for necessary diagnostic testing to guide treatment. Patients tested for HIV were screened using antibody testing, meaning some positive patients tested may have been missed during the window period. Lastly, there may have been patients admitted who did not undergo HIV testing or did not disclose their HIV-positive status who were nevertheless HIV-positive.

An additional benefit of this study involves the development of a low-cost, easily manageable database of de-identified patient information that could be used as a model for data collection in other resource-limited hospitals. This model could be expanded to collect data regarding any number of patient populations, not only the HIV-positive population. This study can serve as a foundation for further research to investigate the causes of the observed clinical presentations in this cohort of hospitalized patients—such as the role of patients’ level of access to HIV diagnostic testing and HAART and the prevalence of treatment failure, default, and non-adherence. Ultimately, such research will improve the lives of individuals in Ghana and continue to curtail the HIV epidemic.

Conclusions

In this population of HIV-positive patients presenting for care at a tertiary care center in Ghana, mortality rate was 35.5%, while 40.6% of patients received a new diagnosis of HIV on admission. Pulmonary tuberculosis was a major comorbidity, while neurological symptomology was a predictor of mortality. These findings argue for greater primary case detection, as well as allocation of resources for imaging and treatment of neurological conditions in HIV-positive patients.

Abbreviations

HAART: 

Highly Active Antiretroviral Therapy

HIV: 

Human Immunodeficiency Virus

ICSOL: 

Intracranial Space Occupying Lesion

KATH: 

Komfo Anokye Teaching Hospital

UNAIDS: 

Joint United Nations Programme on HIV/AIDS

WHO: 

World Health Organization

Declarations

Acknowledgements

The authors wish to thank the Department of Medicine at Komfo Anokye Teaching Hospital for their support of this work and the healthcare workers.

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

RP and AS formulated and designed the study. AS, JN, E Adomako, CA, EO, SA and E Antonio contributed to data collection. JN authored the primary manuscript. WA performed data analysis, constructed data tables, and authored the statistical methods section. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethics clearance was obtained from the Kwame Nkrumah University of Science and Technology and the Komfo Anokye Teaching Hospital ethics review committee (CHRPE/347/15). Consent from individual patients was waived, as this project involved an internal, retrospective review of patient charts without any acquisition of identifying patient information. Permission was obtained from the Department of Medicine and the Research and Development Unit at Komfo Anokye Teaching Hospital, Kumasi to review patient folders. Data were accessible only to authorized members of the core study team.

Consent for publication

Permission was obtained from the Department of Medicine and the Research and Development Unit at Komfo Anokye Teaching Hospital, Kumasi to review patient folders.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Komfo Anokye Teaching Hospital, Kumasi, Ghana
(2)
Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
(3)
University of Rochester Medical Center, Rochester, NY, USA
(4)
Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA
(5)
Clinical Research Office (CRO), Loyola University Chicago Health Sciences Division, Chicago, USA

References

  1. UNAIDS. Fact Sheet - World AIDS day 2017. 2017. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Assessed 31 July 2018.
  2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352(9142):1725–30.View ArticlePubMedGoogle Scholar
  3. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897–908.View ArticlePubMedGoogle Scholar
  4. Lewden C, Drabo YJ, Zannou DM, Maiga MY, Minta DK, Sow PS, et al. Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. J Int AIDS Soc. 2014;17:18797.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Abo Y, Zannou Djimon M, Messou E, Balestre E, Kouakou M, Akakpo J, et al. Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration. BMC Infect Dis. 2015;15:176.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Marshall CS, Curtis AJ, Spelman T, O'Brien DP, Greig J, Shanks L, et al. Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings. PLoS One. 2013;8(7):e68445.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Dicko F, Desmonde S, Koumakpai S, Dior-Mbodj H, Koueta F, Baeta N, et al. Reasons for hospitalization in HIV-infected children in West Africa. J Int AIDS Soc. 2014;17:18818.View ArticlePubMedPubMed CentralGoogle Scholar
  8. van der Kop ML, Thabane L, Awiti PO, Muhula S, Kyomuhangi LB, Lester RT, et al. Advanced HIV disease at presentation to care in Nairobi, Kenya: late diagnosis or delayed linkage to care?-a cross-sectional study. BMC Infect Dis. 2016;16(1):169.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Op de Coul EL, van Sighem A, Brinkman K, van Benthem BH, van der Ende ME, Geerlings S, et al. Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996–2014: results from a national observational cohort. BMJ Open. 2016;6(1):e009688.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, Yang LY, et al. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. Clin Infect Dis. 2011;52(3):341–8.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Oliveira MT, Latorre Mdo R, Greco DB. The impact of late diagnosis on the survival of patients following their first AIDS-related hospitalization in Belo Horizonte. Brazil AIDS Care. 2012;24(5):635–41.View ArticlePubMedGoogle Scholar
  12. Moreira AL, Fronteira I, Augusto GF, Martins MR. Unmatched Case-Control Study on Late Presentation of HIV Infection in Santiago, Cape Verde (2004-2011). Int J Environ Res Public Health. 2016;13(3). https://doi.org/10.3390/ijerph13030320.
  13. Country AIDS response progress report: Ghana [Internet]. 2015 . http://www.unaids.org/sites/default/files/country/documents/GHA_narrative_report_2015.pdf. Assessed 31 July 2018.
  14. Teja VD, Sudha T, Lakshmi V. Causes and pattern of mortality in HIV-infected, hospitalized patients in a tertiary care hospital: a fourteen year study. Indian J Med Sci. 2007;61(10):555–61.View ArticlePubMedGoogle Scholar
  15. Saleri N, Capone S, Pietra V, De Iaco G, Del Punta V, Rizzi M, et al. Outcome and predictive factors of mortality in hospitalized HIV-patients in Burkina Faso. Infection. 2009;37(2):142–7.View ArticlePubMedGoogle Scholar
  16. Kra OAY, Yao KH, Ouattara B, Abouo F, Tanon KA, Eholié S, Bissagnené E. Clinical, biological, therapeutic and evolving profile of patients with HIV infection hospitalized at infectious and tropical diseases unit in Abidjan (Ivory Coast). Bull Soc Pathol Exot. 2013;104(5):366–70.Google Scholar
  17. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in cote d'Ivoire. Clinical Infect Dis. 2012;54(5):714–23.View ArticleGoogle Scholar
  18. Mamoojee Y, Shakoor S, Gorton RL, Sarfo S, Appiah LT, Norman B, et al. Short communication: low seroprevalence of cryptococcal antigenaemia in patients with advanced HIV infection enrolling in an antiretroviral programme in Ghana. Tropical Med Int Health. 2011;16(1):53–6.View ArticleGoogle Scholar
  19. Joint United Nations Programme on HIV/AIDS. 90–90-90: An ambitious treatment target to help end the AIDS epidemic. 2014. http://www.unaids.org/en/resources/documents/2017/90-90-90. Assessed 31 July 2018.
  20. Insight Start Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.View ArticleGoogle Scholar
  21. Temprano Anrs Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early Antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.View ArticleGoogle Scholar
  22. World Health Organization. WHO Early Release Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV September 2015 Geneva 2015 . http://www.whoint/hiv/pub/guidelines/earlyrelease-arv/en/. Assessed 31 July 2018.
  23. Lin DY, Wei LJ, Ying Z. Checking the cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80(3):557–72.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement